Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanadelumab in Factor XII-associated cold autoinflammatory syndrome (FACAS)
2019-001235-31Phase 2Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Nov 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of lanadelumab in Factor XII-associated cold autoinflammatory syndrome (FACAS), sponsored by Charité – Universitätsmedizin Berlin. Started Nov 2019; status: completed.
02
Drugs
lanadelumab
03
Conditions
Factor XII-associated cold autoinflammatory syndrome (FACAS)
Beyond the preview
Go deeper on 2019-001235-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001235-31.